Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
8.76B
Market cap8.76B
Price-Earnings ratio
40.01
Price-Earnings ratio40.01
Dividend yield
Dividend yield
Average volume
5.20M
Average volume5.20M
High today
$62.83
High today$62.83
Low today
$61.21
Low today$61.21
Open price
$62.11
Open price$62.11
Volume
247.73K
Volume247.73K
52 Week high
$76.76
52 Week high$76.76
52 Week low
$9.57
52 Week low$9.57

Stock Snapshot

Arrowhead Pharmaceuticals(ARWR) stock is priced at $62.56, giving the company a market capitalization of 8.76B. It carries a P/E multiple of 40.01.

On 2026-02-12, Arrowhead Pharmaceuticals(ARWR) stock moved within a range of $61.21 to $62.83. With shares now at $62.56, the stock is trading +2.2% above its intraday low and -0.4% below the session's peak.

Trading volume for Arrowhead Pharmaceuticals(ARWR) stock has reached 247.73K, versus its average volume of 5.2M.

Over the past 52 weeks, Arrowhead Pharmaceuticals(ARWR) stock has traded between a high of $76.76 and a low of $9.57.

Over the past 52 weeks, Arrowhead Pharmaceuticals(ARWR) stock has traded between a high of $76.76 and a low of $9.57.

ARWR News

Simply Wall St 5h
Arrowhead Pharmaceuticals' Strong Earnings Are Of Good Quality

Arrowhead Pharmaceuticals, Inc.'s ( ) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We did some digging an...

Arrowhead Pharmaceuticals' Strong Earnings Are Of Good Quality
Simply Wall St 1d
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has been added to the S&P 400 index and its related sector indices. At the same time, the company has been removed fr...

Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus
The Motley Fool 6d
Arrowhead Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, February 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Christopher Anzalone Chief Operating...

Arrowhead Q1 2026 Earnings Call Transcript

Analyst ratings

64%

of 14 ratings
Buy
64.3%
Hold
28.6%
Sell
7.1%

More ARWR News

Seeking Alpha 6d
Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline

Earnings Call Insights Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline Feb. 06, 2026...

Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.